NEJM: 乳腺癌放疗增加缺血性心脏病风险

2013-03-21 shumufeng 丁香园

缺血性心脏病的累积发生率 乳腺癌放疗往往涉及一些偶然的心脏对电离辐射的暴露。这种暴露对以后缺血性心脏病风险的影响尚不确定。英国牛津大学Darby博士及其同事对此进行了深入研究,他们发现在乳腺癌放疗期间心脏电离辐射暴露可导致以后缺血性心脏病的发生率增加。该病发生率的增加与心脏受照平均剂量成比例,于暴露后数年内开始,并持续至少20年。此前存在心脏风险因素的女性因放疗导致的风险绝对增加值大于其他女


缺血性心脏病的累积发生率
乳腺癌放疗往往涉及一些偶然的心脏对电离辐射的暴露。这种暴露对以后缺血性心脏病风险的影响尚不确定。英国牛津大学Darby博士及其同事对此进行了深入研究,他们发现在乳腺癌放疗期间心脏电离辐射暴露可导致以后缺血性心脏病的发生率增加。该病发生率的增加与心脏受照平均剂量成比例,于暴露后数年内开始,并持续至少20年。此前存在心脏风险因素的女性因放疗导致的风险绝对增加值大于其他女性。研究成果在线发表于国际权威杂志NEJM 2013年最新一期。
对自1958~2001年期间在瑞典和丹麦接受乳腺癌放疗的2168名女性就主要冠脉事件(即心肌梗死、冠脉血运重建或死于缺血性心脏病)进行了一项基于人群的病例对照研究。该研究包括了963名有主要冠脉事件的女性和1205名对照者。我们从医院病例记录获取了每例患者信息。对于每一名女性,我们根据她的放疗图表对全心和冠脉左前降支的平均照射剂量进行了估算。
全心受照平均剂量的总均值为4.9 Gy(范围0.03~27.72)。主要冠脉事件发生率呈线性按7.4%/Gy的比例随心脏受照平均剂量的增加而增加(95%可信区间2.9~14.5,P<0.001),并且无明显的阈值。这种增加始于放疗后前5年内,并持续至放疗后第3个10年。在放疗时有心脏风险因素的女性和无心脏风险因素的女性主要冠脉事件发生率/Gy的增加比例相似。
研究人员由此得出结论,在乳腺癌放疗期间心脏电离辐射暴露可导致以后缺血性心脏病的发生率增加。该病发生率的增加与心脏平均照射剂量成比例,于暴露后数年内开始,并持续至少20年。此前存在心脏风险因素的女性因放疗导致的风险绝对增加值大于其他女性。
述评:
研究人员报道尽管放疗在治疗乳腺癌方面有很好的效果,但是它会使治疗后患缺血性心肌病的风险增加。根据英国牛津大学临床实验中心Sarah Darby博士及其同事的一项基于人群的病例对照研究显示心脏每暴露于1Gy的辐射量,患冠状动脉疾病的风险增加7%,且小剂量辐射也可能导致发病。Darby博士及其同事3月14日发表在《新英格兰医学杂志》上的文章指出放疗后前5年冠状动脉疾病发病的几率最大,但这种风险可持续长达20年。研究人员还指出心脏病高风险的女性放疗后患冠状动脉疾病的风险更大。Darby博士及其同事总结说:医生可以综合考虑辐射剂量、心脏病发病风险和肿瘤控制几方面来确定乳腺癌放疗的治疗方案。
美国休斯顿MD 安德森肿瘤中心的Jean-Bernard Durand医生评论说,这项瑞典和丹麦2168名乳腺癌存活者的研究给了临床医生们一个提醒信号。他对MedPage Today的记者说,我们必须对女性的健康问题格外警惕,确保我们对乳腺癌患者有足够的重视。我们要确保她们能够接受正确的治疗,能够得到考虑多方面有利于延长寿命的治疗方案。Durand医生指出,在美国女性比男性接受心血管病预防治疗措施的数量要少,而心血管病预防治疗措施可能会降低放疗后心脏缺血性疾病的发病风险。他说,将乳腺癌放疗患者的胆固醇含量,尿糖和血压控制在正常范围可以减少心血管病的发病风险,这项研究强调了乳腺癌患者放疗后随访的重要性。Durand医生还说,在年轻女性中早点发现和治疗乳腺癌比等到她们年龄大了再去治疗更能有效改善女性的存活。
研究人员发现,早期乳腺癌放疗可以减少复发和死亡率,但是放疗时辐射对心脏的影响还不清楚。他们比较了1958年至2001年间接受乳腺癌放疗的963名女性和1205名对照心脏冠状动脉病情况。两组人群通过国籍,发病年龄,诊断时间和有无复发或其他癌症对比。发现接受乳腺癌放疗后患心脏冠状动脉病的病人均在乳腺癌复发或其他癌症发生前发病,所患疾病主要是:心梗、冠状动脉狭窄或缺血性心脏病死亡。冠状动脉疾病在乳腺癌放疗女性中,44%在化疗后10年内发病,33%在10到20年间发病,23%在20年后发病。导致冠状动脉疾病的放疗的平均辐射剂量为:左侧乳腺肿瘤6.6Gy,乳腺肿瘤2.9Gy,总剂量4.9Gy。
辐射剂量每增加1 Gy患病几率增加7.4%,并且5年内发病率增加16.3%,5至10年间发病率增加15.5%,10至20年间发病率增加1.2%,20年后发病率增加8.2%。至于肿瘤的性质对冠状动脉疾病发病的影响,只发现肿瘤的位置对发病率有影响,左侧乳腺癌的病人放疗后患病几率更高(P<0.001)。化疗前有缺血性心脏病的病人比没有缺血性心脏病的病人患病率高6.67倍。患其他心血管疾病、糖尿病、慢性阻塞性肺病或抽烟的乳腺癌患者放疗后患冠状动脉疾病的风险也增高。研究人员指出,这项研究中40岁以下的女性数量很少,因此这项研究结果可能不能直接用于40岁以下人群。
波士顿Brigham女子医院的Javid Moslehi医生在这本杂志中评论说,这些发现可能会对将来的研究起到抛砖引玉的作用。他还指出,除了缺血性心脏病放疗还和心包疾病、外周血管疾病、心肌病、心瓣膜功能障碍和心律不齐的发生有关。他说,这些疾病不是这项研究的内容也与化疗无关,这项研究提示应该在乳腺癌诊断后放疗开始前要对心脏的功能进行检查。

BACKGROUND
Radiotherapy for breast cancer often involves some incidental exposure of the heart to ionizing radiation. The effect of this exposure on the subsequent risk of ischemic heart disease is uncertain.
METHODS
We conducted a population-based case–control study of major coronary events (i.e., myocardial infarction, coronary revascularization, or death from ischemic heart disease) in 2168 women who underwent radiotherapy for breast cancer between 1958 and 2001 in Sweden and Denmark; the study included 963 women with major coronary events and 1205 controls. Individual patient information was obtained from hospital records. For each woman, the mean radiation doses to the whole heart and to the left anterior descending coronary artery were estimated from her radiotherapy chart.
RESULTS
The overall average of the mean doses to the whole heart was 4.9 Gy (range, 0.03 to 27.72). Rates of major coronary events increased linearly with the mean dose to the heart by 7.4% per gray (95% confidence interval, 2.9 to 14.5; P<0.001), with no apparent threshold. The increase started within the first 5 years after radiotherapy and continued into the third decade after radiotherapy. The proportional increase in the rate of major coronary events per gray was similar in women with and women without cardiac risk factors at the time of radiotherapy.
CONCLUSIONS
Exposure of the heart to ionizing radiation during radiotherapy for breast cancer increases the subsequent rate of ischemic heart disease. The increase is proportional to the mean dose to the heart, begins within a few years after exposure, and continues for at least 20 years. Women with preexisting cardiac risk factors have greater absolute increases in risk from radiotherapy than other women. (Funded by Cancer Research UK and others.)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=5562, encodeId=5434556289, content=调强或三维适形的结果如果, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sat Mar 30 14:03:00 CST 2013, time=2013-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892563, encodeId=bfd51892563cb, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Feb 14 22:11:00 CST 2014, time=2014-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318338, encodeId=53f6131833803, content=<a href='/topic/show?id=7b80e9367d2' target=_blank style='color:#2F92EE;'>#缺血性心脏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79367, encryptionId=7b80e9367d2, topicName=缺血性心脏病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Sat Mar 23 01:11:00 CST 2013, time=2013-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1559668, encodeId=f15c15596689e, content=<a href='/topic/show?id=b8435162302' target=_blank style='color:#2F92EE;'>#心脏病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51623, encryptionId=b8435162302, topicName=心脏病风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94f015012402, createdName=mgqwxj, createdTime=Sat Mar 23 01:11:00 CST 2013, time=2013-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1565677, encodeId=614c15656e7b7, content=<a href='/topic/show?id=b8435162302' target=_blank style='color:#2F92EE;'>#心脏病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51623, encryptionId=b8435162302, topicName=心脏病风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94f015012402, createdName=mgqwxj, createdTime=Sat Mar 23 01:11:00 CST 2013, time=2013-03-23, status=1, ipAttribution=)]
    2013-03-30 匿名用户

    调强或三维适形的结果如果

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=5562, encodeId=5434556289, content=调强或三维适形的结果如果, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sat Mar 30 14:03:00 CST 2013, time=2013-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892563, encodeId=bfd51892563cb, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Feb 14 22:11:00 CST 2014, time=2014-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318338, encodeId=53f6131833803, content=<a href='/topic/show?id=7b80e9367d2' target=_blank style='color:#2F92EE;'>#缺血性心脏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79367, encryptionId=7b80e9367d2, topicName=缺血性心脏病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Sat Mar 23 01:11:00 CST 2013, time=2013-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1559668, encodeId=f15c15596689e, content=<a href='/topic/show?id=b8435162302' target=_blank style='color:#2F92EE;'>#心脏病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51623, encryptionId=b8435162302, topicName=心脏病风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94f015012402, createdName=mgqwxj, createdTime=Sat Mar 23 01:11:00 CST 2013, time=2013-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1565677, encodeId=614c15656e7b7, content=<a href='/topic/show?id=b8435162302' target=_blank style='color:#2F92EE;'>#心脏病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51623, encryptionId=b8435162302, topicName=心脏病风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94f015012402, createdName=mgqwxj, createdTime=Sat Mar 23 01:11:00 CST 2013, time=2013-03-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=5562, encodeId=5434556289, content=调强或三维适形的结果如果, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sat Mar 30 14:03:00 CST 2013, time=2013-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892563, encodeId=bfd51892563cb, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Feb 14 22:11:00 CST 2014, time=2014-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318338, encodeId=53f6131833803, content=<a href='/topic/show?id=7b80e9367d2' target=_blank style='color:#2F92EE;'>#缺血性心脏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79367, encryptionId=7b80e9367d2, topicName=缺血性心脏病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Sat Mar 23 01:11:00 CST 2013, time=2013-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1559668, encodeId=f15c15596689e, content=<a href='/topic/show?id=b8435162302' target=_blank style='color:#2F92EE;'>#心脏病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51623, encryptionId=b8435162302, topicName=心脏病风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94f015012402, createdName=mgqwxj, createdTime=Sat Mar 23 01:11:00 CST 2013, time=2013-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1565677, encodeId=614c15656e7b7, content=<a href='/topic/show?id=b8435162302' target=_blank style='color:#2F92EE;'>#心脏病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51623, encryptionId=b8435162302, topicName=心脏病风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94f015012402, createdName=mgqwxj, createdTime=Sat Mar 23 01:11:00 CST 2013, time=2013-03-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=5562, encodeId=5434556289, content=调强或三维适形的结果如果, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sat Mar 30 14:03:00 CST 2013, time=2013-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892563, encodeId=bfd51892563cb, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Feb 14 22:11:00 CST 2014, time=2014-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318338, encodeId=53f6131833803, content=<a href='/topic/show?id=7b80e9367d2' target=_blank style='color:#2F92EE;'>#缺血性心脏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79367, encryptionId=7b80e9367d2, topicName=缺血性心脏病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Sat Mar 23 01:11:00 CST 2013, time=2013-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1559668, encodeId=f15c15596689e, content=<a href='/topic/show?id=b8435162302' target=_blank style='color:#2F92EE;'>#心脏病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51623, encryptionId=b8435162302, topicName=心脏病风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94f015012402, createdName=mgqwxj, createdTime=Sat Mar 23 01:11:00 CST 2013, time=2013-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1565677, encodeId=614c15656e7b7, content=<a href='/topic/show?id=b8435162302' target=_blank style='color:#2F92EE;'>#心脏病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51623, encryptionId=b8435162302, topicName=心脏病风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94f015012402, createdName=mgqwxj, createdTime=Sat Mar 23 01:11:00 CST 2013, time=2013-03-23, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=5562, encodeId=5434556289, content=调强或三维适形的结果如果, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sat Mar 30 14:03:00 CST 2013, time=2013-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892563, encodeId=bfd51892563cb, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Feb 14 22:11:00 CST 2014, time=2014-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318338, encodeId=53f6131833803, content=<a href='/topic/show?id=7b80e9367d2' target=_blank style='color:#2F92EE;'>#缺血性心脏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79367, encryptionId=7b80e9367d2, topicName=缺血性心脏病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Sat Mar 23 01:11:00 CST 2013, time=2013-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1559668, encodeId=f15c15596689e, content=<a href='/topic/show?id=b8435162302' target=_blank style='color:#2F92EE;'>#心脏病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51623, encryptionId=b8435162302, topicName=心脏病风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94f015012402, createdName=mgqwxj, createdTime=Sat Mar 23 01:11:00 CST 2013, time=2013-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1565677, encodeId=614c15656e7b7, content=<a href='/topic/show?id=b8435162302' target=_blank style='color:#2F92EE;'>#心脏病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51623, encryptionId=b8435162302, topicName=心脏病风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94f015012402, createdName=mgqwxj, createdTime=Sat Mar 23 01:11:00 CST 2013, time=2013-03-23, status=1, ipAttribution=)]

相关资讯

NEJM:他汀降低癌症患者死亡率

一项丹麦的大样本研究发现,对癌症患者应用他汀类药物减少疾病相关死亡率可达15%。 研究发现,与没有应用他汀类药物的患者相比,13种癌症患者应用他汀类药物后,癌症特异的死亡率降低了。所有原因死亡的风险比是0.85,死于癌症是0.85。 研究结果发表在2011年11月8日的《新英格兰医学杂志》上。 Neil E Caporaso博士(国家癌症研究所,马里兰州贝塞斯达)在一篇社论指出,先前的研究显

NEJM:免疫功能低下患者诺如病毒胃肠炎的防治

传染性胃肠炎是一种常见的急性疾病,虽然有自限性的特征,但可能使免疫功能低下患者更加虚弱并危及生命。诺如病毒是引发免疫功能强健和免疫功能低下患者胃肠炎的主要致病源。在美国,诺如病毒是引发成人急诊室就诊的急性胃肠炎的单一最常见病源微生物,也是引发婴儿和儿童严重腹泻的第二大主要轮状病毒。 在发展中国家,评估认为诺如病毒导致了超过200 000 例5岁以下儿童死亡,预测当轮状病毒经疫苗预防得到控制后,此

NEJM:脐带血与间充质细胞体外共培养可改善脐带血移植结局

限制脐血移植临床应用的主要因素是其有核细胞数量太低。美国德克萨斯州立大学de Lima博士等研究者假设通过间充质细胞与脐带血体外共培养移植或可改善移植应用,他们的研究发现,间充质基质细胞与脐带血细胞共培养移植或是安全有效的。与仅接受未处理脐带血移植相比,扩增脐带血与未处理脐带血共移植可显着性改善移植结局。论文发表于国际权威杂志NEJM 2012年12月19日在线版。 研究者对31例接受2个单位脐

NEJM:阿比特龙可使早期前列腺癌患者有显著获益

一项重要的新临床试验显示,一种已经用于治疗晚期前列腺癌的药物也可使早期前列腺癌患者明显获益。去年5月英国国家卫生与临床优化研究所(NICE)批准将伦敦癌症研究所研制的阿比特龙列为国家健康保险(NHS)的医保用药,其治疗适应症是对标准激素治疗和紫杉醇化疗停止反应的前列腺癌。 癌症研究所(ICR)和皇家马斯登NHS信托基金进行了一项新的III期临床试验,结果显示,化疗前给无症状和轻度症状男性患者进行

NEJM:中山大学发表一罕见病例

  在最新一期《新英格兰医学杂志》(N Engl J Med 2012;367:e18)上刊登了中山大学附属第三医院耳鼻咽喉-头颈外科医生杨钦泰和李鹏合作撰写的题为“A Laryngeal Fluke”一例罕见病例。   病例报道的患者因进食生鱼片后出现严重的咽痒、咳嗽症状,经多方治疗经久不愈。当患者到三院耳鼻咽喉-头颈外科门诊喉镜检查

全球大规模早期糖尿病临床试验结果发布

在日前举行的第72届美国糖尿病学会(ADA)年会上,ORIGIN(甘精胰岛素初始干预转归研究)研究结果首次发布,这一研究同时在线发表于《新英格兰医学杂志》(NEJM)。ORIGIN是一项史无前例的心血管疾病(CV)转归研究,为期6.2年,旨在评估甘精胰岛素——来得时——治疗与标准治疗相比,对CV风险的影响。研究覆盖了全世界40个国家,是在早期糖尿病患者中开展的全世界最大规模、最长期的随机临床试验,